Risk of asymptomatic and/or symptomatic cardiomyopathy in survivors treated with <15 Gy chest RT using conventional fractionation.
In survivors treated with anthracyclines and chest RT, risk of cardiomyopathy by dose of anthracycline or chest RT administered.
Effect of age at anthracycline and/or chest radiation exposure on cardiomyopathy risk.
Differences in cardiomyopathy risk by anthracycline/ anthraquinone analogue.
Change in radiation-related cardiomyopathy risk by treatment era due to advances in radiation administration techniques.
Long-term (>5 years) efficacy of the cardioprotectant dexrazoxane for cardiomyopathy risk reduction.
Prognostic utility of change in intermediate echocardiographic indices of left ventricular systolic and diastolic function (i.e.: abnormal wall stress, decreased thickness-dimension ratio, elevated myocardial perfomrance index, abnormal E/A ratio) on future cardiomyopathy risk in asymptomatic survivors.
Prognostic utility of decrease in LV EF/FS, as detected by CMR or radionuclide angiography on subsequent cardiomyopathy risk in asymptomatic survivors.
Prognostic utility of increase in cardiac troponins or natriuretic peptides during anthracycline or chest radiation administration on long-term (>5 years) cardiomyopathy risk.
Accuracy of serum natriuretic peptide (ANP, BNP, NT-pro-BNP) for identification of asymptomatic cardiomyopathy in childhood cancer survivors treated with anthracyclines and/or radiation.
Lifetime risk of cardiomyopathy in very long-term (>30 years after treatment) childhood cancer survivors treated with anthracyclines and/or radiation.
Rate of deterioration of cardiac function over time.
Cost-effectiveness of different screening frequencies by cardiomyopathy risk.
Assessment of potential harms associated with excessive screening and resulant false-positive findings.
Risk of cardiomyopathy in pregnant survivors treated with anthracyclines or chest radiation.
Utility of closer monitoring and more frequent echocardiographic screening during pregnancy.
Role of pharmacologic interventions to reduce cardiomyopathy risk in asymptomatic survivors with normal cardiac function.
Long-term utility of pharmacologic interventions in symptomatic survivors with abnormal cardiac function.
Need for and type of restrictions in physical activity for childhood cancer survivors considered low-, moderate-, and high-risk for cardiomyopathy.
Benefits of interventions to reduce modifiable risk factors such as smoking, obesity, hypertension, diabetes, or dyslipidemia, in childhood cancer survivors at risk for cardiomyopathy.
Role of genetic susceptibility on subsequent cardiomyopathy risk in survivors treated with anthracyclines and/or chest radiation.
